Publication of List of Manufacturers Granted Licence for the Manufacture of Therapeutic Goods

Overview

The Therapeutic Goods Act 1989 was enacted to regulate the provision of therapeutic goods in Australia, ensuring that these goods are of acceptable quality, safety, and efficacy. This Act was introduced to address the need for a comprehensive legal framework governing the manufacture, importation, supply, and advertising of therapeutic goods, including medicines, medical devices, and blood products. The Therapeutic Goods Administration, as the delegate of the Secretary of the Department of Health, administers this Act, which aims to protect public health by ensuring that therapeutic goods available in Australia meet the necessary standards. The Act provides a clear and consistent regulatory approach to managing the risks associated with the use of therapeutic goods. On 15 February 2018, the Therapeutic Goods Administration published a list of manufacturers granted a Licence to Manufacture Therapeutic Goods, as required by section 38 of the Therapeutic Goods Act 1989. The list includes various entities, such as Factors Group Australia Pty Ltd, The Australian Red Cross Blood Service, Toll Transport Pty Ltd, and others, each granted specific licences for manufacturing therapeutic goods. This publication is part of the ongoing effort to maintain transparency and compliance within the therapeutic goods industry, ensuring that all licensed manufacturers adhere to the regulatory standards set forth by the Act.

Scope and Application

The Therapeutic Goods Act 1989, administered by the Therapeutic Goods Administration within the Department of Health, pertains to the regulation of therapeutic goods in Australia, which include a broad range of products such as medicines, medical devices, blood and blood components, tissues, and human cells. The Act applies to entities and individuals involved in the manufacturing, importation, supply, and advertising of these goods. It encompasses various industries including pharmaceuticals, biotechnology, and medical device manufacturing. The Act operates at a national level, applying across the Commonwealth of Australia, and its regulations are enforced to ensure that therapeutic goods meet safety, quality, and efficacy standards. The legislation specifies certain exclusions, such as goods used for personal, non-commercial purposes, and it also delineates thresholds for licensing and registration requirements. The scope of the Act can be extended or modified through subordinate instruments, which provide further detail and specificity regarding compliance and enforcement. These regulations ensure that the therapeutic goods market in Australia maintains high standards to protect public health.

Key Provisions

Under section 38 of the Therapeutic Goods Act 1989, the Secretary has granted licences to various entities for the manufacture of therapeutic goods. These licences are necessary for companies to legally produce and distribute therapeutic goods, which include medicines, medical devices, and blood products, among others. The listed companies include Factors Group Australia Pty Ltd, several operating divisions of The Australian Red Cross Blood Service, Toll Transport Pty Ltd, Perth Bone & Tissue Bank T/A PlusLife, Boundary Bend Olives Pty, and Orchard Manufacturing Co Pty Ltd. Each entity has been issued a unique licence number and their respective addresses have been detailed in the notice. The obligations imposed on these entities by the Therapeutic Goods Act 1989 are primarily concerned with ensuring the safety, quality, and efficacy of the therapeutic goods they manufacture. These obligations include complying with Good Manufacturing Practice (GMP) standards, maintaining proper records of their manufacturing processes, and ensuring that their products meet the standards set by the Therapeutic Goods Administration (TGA). Additionally, the entities are required to report any adverse events related to their products and to conduct regular self-inspections to ensure ongoing compliance with the Act. Failure to comply with the provisions of the Therapeutic Goods Act 1989 can result in both civil and criminal consequences. Civil penalties can include fines of up to $1,650 for individuals and significantly higher amounts for corporations, depending on the severity of the breach. Criminal offences can lead to penalties of up to $220,000 for individuals and $1,100,000 for corporations. In serious cases, individuals may face imprisonment for up to 12 months, while corporate entities may be subject to longer-term penalties and potentially have their licences revoked. The specific penalties are determined by the severity of the breach and the degree of harm caused by non-compliance.